Completed PHASE2 INTERVENTIONAL 4-arm NCT00953381

Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)

Efficacy and Safety of Ilaprazole for Acute Duodenal Ulcer: A Randomized,Double-Blind,Omeprazole-Controlled,Multicenter,and Phase2 Trial in China

Sponsor: Livzon Pharmaceutical Group Inc.

Conditions Duodenal Ulcer

Interventions 10 mg ilaprazole 20 mg ilaprazole 20 mg omeprazole 5 mg ilaprazole

Updated 5 times since 2017 Last updated: Aug 5, 2009 Started: Oct 31, 2004 Primary completion: Mar 31, 2005 Completion: May 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00953381, this PHASE2 trial focuses on Duodenal Ulcer and remains completed. Sponsored by Livzon Pharmaceutical Group Inc., it has been updated 5 times since 2004, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Oct 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Livzon Pharmaceutical Group Inc.

Data source: Livzon Pharmaceutical Group Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China